Literature DB >> 20023429

Synergy and antagonism of macroautophagy and chaperone-mediated autophagy in a cell model of pathological tau aggregation.

Yipeng Wang1, Marta Martinez-Vicente, Ulrike Krüger, Susmita Kaushik, Esther Wong, Eva-Maria Mandelkow, Ana Maria Cuervo, Eckhard Mandelkow.   

Abstract

Tau aggregation characterizes a series of neurodegenerative diseases including AD and other tauopathies. The distribution of Tau deposits correlates with the loss of neurons in these neurodegenerative diseases, and Tau-induced toxicity depends on its ability to aggregate. We have used an inducible cell model to study the expression of Tau variants, the buildup of aggregates, and their removal by the autophagy-lysosomal system. Incomplete chaperone-mediated autophagy of Tau generates amyloidogenic fragments that promote aggregation. The Tau aggregates are removed from cells by macroautophagy. Thus the two autophagic pathways could become possible therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20023429     DOI: 10.4161/auto.6.1.10815

Source DB:  PubMed          Journal:  Autophagy        ISSN: 1554-8627            Impact factor:   16.016


  35 in total

Review 1.  Chaperone-mediated autophagy: machinery, regulation and biological consequences.

Authors:  Wenming Li; Qian Yang; Zixu Mao
Journal:  Cell Mol Life Sci       Date:  2010-10-26       Impact factor: 9.261

Review 2.  Autophagy in Alzheimer's disease.

Authors:  Ameneh Zare-Shahabadi; Eliezer Masliah; Gail V W Johnson; Nima Rezaei
Journal:  Rev Neurosci       Date:  2015       Impact factor: 4.353

Review 3.  The Autophagy Lysosomal Pathway and Neurodegeneration.

Authors:  Steven Finkbeiner
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-03-02       Impact factor: 10.005

Review 4.  New insights into the pathology of podocyte loss: mitotic catastrophe.

Authors:  Helen Liapis; Paola Romagnani; Hans-Joachim Anders
Journal:  Am J Pathol       Date:  2013-09-03       Impact factor: 4.307

Review 5.  Ubiquitination in disease pathogenesis and treatment.

Authors:  Doris Popovic; Domagoj Vucic; Ivan Dikic
Journal:  Nat Med       Date:  2014-11-06       Impact factor: 53.440

6.  Decreases in valosin-containing protein result in increased levels of tau phosphorylated at Ser262/356.

Authors:  Philip J Dolan; Youngnam N Jin; Woong Hwang; Gail V W Johnson
Journal:  FEBS Lett       Date:  2011-10-05       Impact factor: 4.124

7.  Proteasome inhibition drives HDAC6-dependent recruitment of tau to aggresomes.

Authors:  Chris R Guthrie; Brian C Kraemer
Journal:  J Mol Neurosci       Date:  2011-02-22       Impact factor: 3.444

8.  Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease.

Authors:  Michael C Pace; Guilian Xu; Susan Fromholt; John Howard; Keith Crosby; Benoit I Giasson; Jada Lewis; David R Borchelt
Journal:  Acta Neuropathol       Date:  2018-08-23       Impact factor: 17.088

9.  Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels.

Authors:  Yoshinari Miyata; Xiaokai Li; Hsiu-Fang Lee; Umesh K Jinwal; Sharan R Srinivasan; Sandlin P Seguin; Zapporah T Young; Jeffrey L Brodsky; Chad A Dickey; Duxin Sun; Jason E Gestwicki
Journal:  ACS Chem Neurosci       Date:  2013-03-20       Impact factor: 4.418

10.  Fractalkine signaling and Tau hyper-phosphorylation are associated with autophagic alterations in lentiviral Tau and Aβ1-42 gene transfer models.

Authors:  Michaeline L Hebron; Norah K Algarzae; Irina Lonskaya; Charbel Moussa
Journal:  Exp Neurol       Date:  2013-01-16       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.